Squarepoint
ALLO icon

Squarepoint’s Allogene Therapeutics ALLO Stock Holding History

Squarepoint’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$502K Buy
241,524
+125,145
+108% +$275K ﹤0.01% 3424
2026
Q1 		$284K Buy
116,379
+11,723
+11% +$23.5K ﹤0.01% 3754
2025
Q4 		$143K Sell
104,656
-163,388
-61% -$216K ﹤0.01% 3959
2025
Q3 		$332K Buy
268,044
+249,978
+1,384% +$298K ﹤0.01% 3585
2025
Q2 		$20.4K Sell
18,066
-308,459
-94% -$410K ﹤0.01% 4390
2025
Q1 		$477K Buy
326,525
+306,180
+1,505% +$577K ﹤0.01% 3345
2024
Q4 		$43.3K Sell
20,345
-168,152
-89% -$415K ﹤0.01% 4867
2024
Q3 		$528K Buy
188,497
+61,869
+49% +$165K ﹤0.01% 3049
2024
Q2 		$295K Buy
+126,628
New +$374K ﹤0.01% 3440
2023
Q4 		– Sell
-121,792
Closed -$386K – 3970
2023
Q3 		$386K Buy
121,792
+71,855
+144% +$315K ﹤0.01% 2978
2023
Q2 		$248K Sell
49,937
-6,838
-12% -$37K ﹤0.01% 3087
2023
Q1 		$280K Sell
56,775
-143,589
-72% -$921K ﹤0.01% 2614
2022
Q4 		$1.26M Sell
200,364
-45,958
-19% -$425K 0.01% 1661
2022
Q3 		$2.66M Buy
+246,322
New +$3.35M 0.01% 1131
2022
Q2 		– Sell
-269,320
Closed -$2.45M – 2846
2022
Q1 		$2.45M Buy
+269,320
New +$2.81M 0.01% 1036
2021
Q1 		– Sell
-15,792
Closed -$399K – 3056
2020
Q4 		$399K Buy
15,792
+9,892
+168% +$322K ﹤0.01% 1983
2020
Q3 		$222K Buy
+5,900
New +$222K ﹤0.01% 2014
2020
Q1 		– Sell
-54,596
Closed -$1.42M – 1825
2019
Q4 		$1.42M Buy
54,596
+46,049
+539% +$1.27M 0.01% 1109
2019
Q3 		$233K Sell
8,547
-1,854
-18% -$52.8K ﹤0.01% 2012
2019
Q2 		$279K Sell
10,401
-2,599
-20% -$72.4K ﹤0.01% 1955
2019
Q1 		$376K Buy
+13,000
New +$377K ﹤0.01% 1636

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Squarepoint's ALLO Position: Q2 2026 in Review

Squarepoint increased its Allogene Therapeutics (ALLO) stake by 108% in Q2 2026, buying an estimated $275K and bringing the position to 241,524 shares worth $502K. The position accounts for ﹤0.01% of the portfolio, ranked #3424.

Squarepoint first reported a position in ALLO in Q1 2019 and has held it in 21 quarters since. The position peaked at $2.66M in Q3 2022. 209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Squarepoint held 241,524 shares of Allogene Therapeutics worth $502K as of Q2 2026.
  • Squarepoint bought 125,145 Allogene Therapeutics shares in Q2 2026, an estimated $275K.
  • Allogene Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #3424 holding.
  • Squarepoint first reported a position in Allogene Therapeutics in Q1 2019 and has held it in 21 quarters since.
  • Squarepoint's Allogene Therapeutics position peaked at $2.66M in Q3 2022.
  • 209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.